Tempest Therapeutics, Inc. (TPST) Stock Price & Analysis
Tempest Therapeutics, Inc. (TPST) fell 1.91% to USD 1.03 as of September 8, 2026 at 13:17 UTC, according to Nexqual real-time market data.
TPST last closed at USD 1.03; the session ranged USD 1.01–1.05 on volume of 214,711 shares. Market capitalization is —, with a 52-week range of USD 0.84–12.23 (NCM). Source: Nexqual, September 8, 2026 at 13:17 UTC.
Key Statistics (as of September 8, 2026 at 13:17 UTC)
| Price | USD 1.03 |
|---|---|
| Change | ▼ 1.91% (down) |
| Previous Close | USD 1.03 |
| Open | USD 1.03 |
| Day Range | USD 1.01 – 1.05 |
| 52-Week Range | USD 0.84 – 12.23 |
| Volume | 214,711 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (TPST)
Nexqual's technical model rates TPST "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 13:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.31 (neutral) |
| vs SMA50 | Above (USD 1.02) |
| MACD | 0.01 (positive) |
From Tempest Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect this strategy to allow us to pursue parallel development of multiple programs while managing internal cash resources and extending our operational runway.   Our Pipeline Our product development pipeline consists of the following product candidates:   1. "RCC" renal cancer; "CCA" cholangiocarcinoma; "FPI" First Patient In; "SLE" lupus.
Partnerships
- On February 3, 2026, the Restated Factor Services Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.
- Roche Collaboration Agreement In February 2021, we entered into a collaboration agreement with F.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RNAZ | TransCode Therapeutics, Inc. | USD 2.06 | ▲ 2.49% |
| AVTX | Avalo Therapeutics, Inc. | USD 19.23 | ▼ 0.57% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.86 | ▲ 1.09% |
| ABVC | ABVC Biopharma, Inc. | USD 0.96 | ▲ 10.98% |
| SPRC | SciSparc Ltd. | USD 5.29 | ▼ 9.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 13:17 UTC. This page is informational and not investment advice.